{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:33:56Z","timestamp":1762508036283},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Follicular lymphoma is an indolent non-Hodgkin lymphoma that is most commonly diagnosed in elderly individuals. The majority of patients with follicular lymphoma present with advanced disease. Despite the recent advances in treatment, there remains a substantial unmet need for effective treatments for patients with relapsed\/refractory follicular lymphoma. The PI3K\u03b4 inhibitor idelalisib was approved by the European Medicines Agency in 2014 as a monotherapy for the treatment of adult patients with follicular lymphoma that is refractory to two prior lines of treatment. Real-world evidence from patients with follicular lymphoma treated with idelalisib indicates its utility in these patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>This case report describes an 82-year-old, retired, white, female patient with refractory follicular lymphoma who achieved a partial response with idelalisib treatment. Despite experiencing two incidences of a psoriasis-like rash during idelalisib treatment that required effective management with topical steroids, the patient was able to restart treatment successfully and maintain a continued partial response.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The clinical relevance of the effective management of adverse events in this case demonstrates the opportunity to enable patients to remain on therapy, thereby maintaining long-term response and improving overall outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-2344-9","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T12:07:00Z","timestamp":1582546020000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a\u00a0case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Salma","family":"Machan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosmar","family":"P\u00e9rez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rodriguez-Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Requena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"2344_CR1","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2147\/OTT.S102573","volume":"9","author":"JC Barrientos","year":"2016","unstructured":"Barrientos JC. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther. 2016;9:2945\u201353.","journal-title":"Onco Targets Ther"},{"key":"2344_CR2","unstructured":"Gilead Sciences. Zydelig (idelalisib) summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003843\/WC500175377.pdf."},{"key":"2344_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318.","journal-title":"N Engl J Med"},{"key":"2344_CR4","unstructured":"Gilead Sciences. ZYDELIG\u00ae (idelalisib) prescribing information. http:\/\/www.gilead.com\/~\/media\/CF1E73FFB80B42E2A39F9F5758DB3001.ashx."},{"key":"2344_CR5","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M. Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v83\u201390.","journal-title":"Annals of Oncology"},{"issue":"15 Suppl","key":"2344_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e18030","volume":"33","author":"S Coutre","year":"2015","unstructured":"Coutre S, Barrientos JC, Brown JR, De Vos S, Furman RR, Keating MJ, et al. Safety of idelalisib in B-cell malignancies: integrated analysis of eight clinical trials [abstract]. J Clin Oncol. 2015;33(15 Suppl):e18030.","journal-title":"J Clin Oncol."},{"key":"2344_CR7","unstructured":"European Medicines Agency (EMA). Summary of the risk management plan for Zydelig (idelalisib). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/003843\/WC500169995.pdf."},{"key":"2344_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/DDDT.S136988","volume":"11","author":"RL Van Heertum","year":"2017","unstructured":"Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, et al. Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719\u201328.","journal-title":"Drug Des Devel Ther"},{"key":"2344_CR9","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","volume":"102","author":"G Salles","year":"2017","unstructured":"Salles G, Schuster SJ, De Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102:e156\u20139.","journal-title":"Haematologica."},{"key":"2344_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12328-016-0707-y","volume":"10","author":"MB Hammami","year":"2017","unstructured":"Hammami MB, Al-Taee A, Meeks M, Fesler M, Hurley MY, Cao D, et al. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease. Clin J Gastroenterol. 2017;10:142\u20136.","journal-title":"Clin J Gastroenterol"},{"key":"2344_CR11","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1111\/jdv.14700","volume":"32","author":"L Huilaja","year":"2018","unstructured":"Huilaja L, Lindgren O, Soronen M, Siitonen T, Tasanen K. A slowly developed severe cutaneous adverse reaction to idelalisib. J Eur Acad Dermatol Venereol. 2018;32:e192\u20133.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-2344-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-2344-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-2344-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:33:58Z","timestamp":1614040438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-2344-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2344"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-2344-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent to participate in the study was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in- Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RC has been a speaker for Gilead Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}